New Hampshire legislation · 2025 Regular Session
New Hampshire SB465: classifying xylazine as a schedule III controlled drug.
Status: Failed, April 23, 2026
Sponsors
- William Gannon (R, 23) · primary sponsor
- Daryl Abbas (R, 22)
- Sharon Carson (R, 14)
- David Rochefort (R, 1)
- Mark McConkey (R, 3)
- Lilli Walsh (R, 15)
- Michael Vose (R, 5)
- Terry Roy (R, 31)
- Jennifer Rhodes (R, 17)
Latest actions
- : Inexpedient to Legislate: MA VV 04/23/2026 HJ 11
- : Minority Committee Report: Ought to Pass
- : Majority Committee Report: Inexpedient to Legislate 04/14/2026 (Vote 11-5; RC)
- : Executive Session: 04/14/2026 01:00 pm GP 153
- : Full Committee Work Session: 04/07/2026 01:00 pm GP 153
- : Public Hearing: 03/31/2026 01:30 pm GP 153
- : Introduced (in recess of) 03/12/2026 and referred to Environment and Agriculture HJ 8
- : Ought to Pass with Amendment #2026-0842s, MA, VV; OT3rdg; 03/05/2026; SJ 5
- : Committee Amendment # 2026-0842s, AA, VV; 03/05/2026; SJ 5
- : Committee Report: Ought to Pass with Amendment # 2026-0842s, 03/05/2026; Vote 5-0; CC; SC 8
Subjects: FIREARMS AND WEAPONS
Common questions
- What is SB465?
- SB465 is a bill in the New Hampshire Legislature (2025 Regular Session): classifying xylazine as a schedule III controlled drug.
- What is the status of SB465?
- Failed as of April 23, 2026. Latest action: Inexpedient to Legislate: MA VV 04/23/2026 HJ 11 (April 23, 2026).
- Who sponsored SB465?
- William Gannon (R, 23), with 8 co-sponsors.
- Where is the official record for SB465?
- On the New Hampshire Legislature website: https://gc.nh.gov/bill_status/legacy/bs2016/bill_docket_report.aspx?lsr=2002&sy=2026
Source: official New Hampshire record. Tracked by Delilah, AI for legislation across all 50 states and Congress.